| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Ruri Okubo, Motohiro Okada, Eishi Motomur. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia. Biomolecules. vol 14. issue 9. 2024-09-28. PMID:39334894. |
for several decades, the dopamine hypothesis contributed to the discovery of numerous typical and atypical antipsychotics and was the sole hypothesis for the pathophysiology of schizophrenia. |
2024-09-28 |
2024-10-01 |
Not clear |
| Ruri Okubo, Motohiro Okada, Eishi Motomur. Dysfunction of the NMDA Receptor in the Pathophysiology of Schizophrenia and/or the Pathomechanisms of Treatment-Resistant Schizophrenia. Biomolecules. vol 14. issue 9. 2024-09-28. PMID:39334894. |
however, neither typical nor atypical antipsychotics, other than clozapine, have been effective in addressing negative symptoms and cognitive impairments, which are indices for the prognostic and disability outcomes of schizophrenia. |
2024-09-28 |
2024-10-01 |
Not clear |
| Ahmed Tazi, Faouzi Errachidi, Dipesh Sonawane, Ghizlane Tahri, Sameer Rao, Suyog Meht. An economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (ODT) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in Morocco. Annals of general psychiatry. vol 23. issue 1. 2024-09-18. PMID:39294740. |
an economic model to understand the cost-effectiveness of olanzapine orally dispersible tablets (odt) and olanzapine film coated tablets as a group compared with other oral atypical antipsychotics for treating schizophrenia in morocco. |
2024-09-18 |
2024-09-21 |
Not clear |
| Michael P Caligiuri, Peter J Weiden, Anna Legedza, Sergey Yagoda, Amy Claxto. Handwriting Kinematics in Patients with Schizophrenia Treated with Long-Acting Injectable Atypical Antipsychotics: Results From the ALPINE Study. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144789. |
handwriting kinematics in patients with schizophrenia treated with long-acting injectable atypical antipsychotics: results from the alpine study. |
2024-08-15 |
2024-08-17 |
Not clear |
| Xiaofeng Wang, Mathangi Gopalakrishnan, Benjamin Rich, Jogarao V Gobburu, Frank Larsen, Arash Raoufini. Exposure-Response Modeling in Adults and Adolescents With Schizophrenia to Support the Extrapolation of Brexpiprazole Efficacy to Adolescents. Journal of clinical pharmacology. 2024-07-08. PMID:38973383. |
in order to accelerate drug development and avoid unnecessary drug trials in vulnerable pediatric populations, the us food and drug administration (fda) released a general advice letter to sponsors permitting the effectiveness of atypical antipsychotics for the treatment of schizophrenia in adults to be extrapolated to adolescents. |
2024-07-08 |
2024-07-11 |
Not clear |
| Júlio César Menezes Vieira, Edna Afonso Reis, Augusto Afonso Guerra, Helian Nunes de Oliveira, Cristina Mariano Rua. Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia. Frontiers in psychiatry. vol 15. 2024-07-04. PMID:38962057. |
comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the brazilian national health system in adults with schizophrenia. |
2024-07-04 |
2024-07-10 |
Not clear |
| Júlio César Menezes Vieira, Edna Afonso Reis, Augusto Afonso Guerra, Helian Nunes de Oliveira, Cristina Mariano Rua. Comparative effectiveness of clozapine and non-clozapine atypical antipsychotics provided by the Brazilian National Health System in adults with schizophrenia. Frontiers in psychiatry. vol 15. 2024-07-04. PMID:38962057. |
we aimed to assess the survival of patients with schizophrenia using clozapine compared with non-clozapine atypical antipsychotics provided by the brazilian national health system using real-world data. |
2024-07-04 |
2024-07-10 |
Not clear |
| Kiumarth Amini, Mohammad-Javad Motallebi, Kimia Bakhtiari, Minoo Sadat Hajmiri, Maryam Zamanirafe, Mahdis Sharifikia, Akram Ranjbar, Amir Keshavarzi, Mahtabalsadat Mirjalili, Maryam Mehrpooy. Effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia. Human psychopharmacology. 2024-06-28. PMID:38940745. |
effects of atypical antipsychotics on serum asprosin level and other metabolic parameters in patients with schizophrenia. |
2024-06-28 |
2024-06-30 |
human |
| Xi Chen, Hongna Huang, Zhengping Pu, Yuan Shi, Lijun Wang, Shun Yao, Donghong Cu. Increased risk of atypical antipsychotics-induced metabolic syndrome associated with MIF CATT >5/6 among females with chronic schizophrenia. Schizophrenia research. vol 270. 2024-06-18. PMID:38889656. |
the utilization of atypical antipsychotics (aaps) often leads to metabolic syndrome (mets) in schizophrenia (sz) patients. |
2024-06-18 |
2024-06-21 |
Not clear |
| Xi Chen, Pingyi Gao, Yadan Qi, Zezhi Li, Hongna Huang, Yuan Shi, Lijun Wang, Donghong Cui, Dake Q. High circulating MIF levels indicate the association with atypical antipsychotic-induced adverse metabolic effects. Translational psychiatry. vol 14. issue 1. 2024-05-27. PMID:38802393. |
atypical antipsychotics (aaps) are primary medications for schizophrenia (sz). |
2024-05-27 |
2024-05-31 |
Not clear |
| Xue Xin Goh, Shiau Foon Tee, Pek Yee Tang, Kok Yoon Chee, Kenny Kien Woon Lo. Impact of body mass index elevation, Vitamin D receptor polymorphisms and antipsychotics on the risk of Vitamin D deficiency in schizophrenia patients. Journal of psychiatric research. vol 175. 2024-05-18. PMID:38761517. |
we found significantly lower serum vitamin d level in patients with schizophrenia (p < 0.01), especially those taking atypical antipsychotics (p = 0.02) and combined antipsychotics (p = 0.02) and obese (bmi ≥27.5 kg/m |
2024-05-18 |
2024-05-27 |
Not clear |
| I Yu Dorozhenok, A V Strukov. [Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 124. issue 4. 2024-04-27. PMID:38676675. |
[atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. |
2024-04-27 |
2024-04-30 |
Not clear |
| I Yu Dorozhenok, A V Strukov. [Atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia (using the aripiprazole model)]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 124. issue 4. 2024-04-27. PMID:38676675. |
the review discusses aspects of the use of atypical antipsychotics in the treatment of depression in affective disorders and schizophrenia using the model of aripiprazole, a partial agonist of dopamine receptors. |
2024-04-27 |
2024-04-30 |
Not clear |
| Merve Direktor, Peter Gass, Dragos Int. Understanding the therapeutic action of antipsychotics: from molecular to cellular targets with focus on the islands of Calleja. The international journal of neuropsychopharmacology. 2024-04-17. PMID:38629703. |
here we discuss results suggesting a main role of the islands of calleja, still poorly studied gabaergic granule cell clusters in the ventral striatum, as cellular targets of several innovative atypical antipsychotics (clozapine, cariprazine and xanomeline/emraclidine) effective in treating also negative symptoms of schizophrenia. |
2024-04-17 |
2024-04-19 |
Not clear |
| Agata Zięba, Damian Bartuzi, Piotr Stępnicki, Dariusz Matosiuk, Tomasz M Wróbel, Tuomo Laitinen, Marián Castro, Agnieszka Anna Kaczo. Discovery and in vitro Evaluation of Novel Serotonin 5-HT2A Receptor Ligands Identified Through Virtual Screening. ChemMedChem. 2024-04-15. PMID:38619283. |
ligands of this protein, particularly atypical antipsychotics, are useful in the treatment of numerous mental disorders, including schizophrenia and major depressive disorder. |
2024-04-15 |
2024-04-17 |
Not clear |
| Justina A Warnick, Rachel I Gifeisman, Khevna P Joshi, Sophie A Roe, Rick A Hiciano, Christopher P Conroy, Sohrab Zahed. Dual Atypical Antipsychotics in Treatment-Resistant Schizophrenia: A Correctional Case Report and Review of Literature. Journal of correctional health care : the official journal of the National Commission on Correctional Health Care. 2024-04-02. PMID:38563618. |
dual atypical antipsychotics in treatment-resistant schizophrenia: a correctional case report and review of literature. |
2024-04-02 |
2024-04-04 |
Not clear |
| Yong Zhao, Yifan Li, Jing Du, Chuanlong Fang, Wansheng Li, Mengyu Lv, Yue Wu, Kai Wang, Tingting Wu, Yanghua Tian, Juanjuan Zhan. Modulation of hemispheric asymmetry in executive control of attention in schizophrenia with atypical antipsychotic treatment: Potential benefits of olanzapine. Schizophrenia research. Cognition. vol 36. 2024-03-12. PMID:38469136. |
deficits in executive control of attention have been reported in schizophrenia patients, but can be ameliorated by treatment of atypical antipsychotics along with the symptoms. |
2024-03-12 |
2024-03-14 |
Not clear |
| Diana Siriwardena, Chahaya M Gauci, Ali Mohtashami, Sarit Badiani, Shahrir Kabi. Clozapine-Induced Refractory Colonic Pseudo-Obstruction. Cureus. vol 16. issue 2. 2024-03-04. PMID:38435172. |
the management of treatment-resistant schizophrenia (trs) is challenging as the medications involved, often atypical antipsychotics, have a host of associated adverse effects. |
2024-03-04 |
2024-03-06 |
Not clear |
| Sylvie Perreault, Laurie-Anne Boivin Proulx, Judith Brouillette, Stéphanie Jarry, Marc Dorai. Antipsychotics and Risks of Cardiovascular and Cerebrovascular Diseases and Mortality in Dwelling Community Older Adults. Pharmaceuticals (Basel, Switzerland). vol 17. issue 2. 2024-02-24. PMID:38399393. |
antipsychotics were not linked with cvd/cev risk, except for atypical antipsychotics in patients with schizophrenia and typical antipsychotics in patients with dementia. |
2024-02-24 |
2024-02-26 |
Not clear |
| b' Kristin Richards, Michael Johnsrud, Christopher Zacker, Rahul Sasan\\xc3\\xa. Association Between Persistence with Oral Atypical Antipsychotic Medications and Hospital and Emergency Department Utilization in Medicaid Patients with Schizophrenia. Patient preference and adherence. vol 18. 2024-01-23. PMID:38259956.' |
to examine 1-year persistence with oral atypical antipsychotics (oaaps) for medicaid patients with schizophrenia and assess the association between oaap persistence and hospital and emergency department (ed) resource utilization. |
2024-01-23 |
2024-01-25 |
Not clear |